logo-loader
viewProvident Financial

Liberum upgrades Provident Financial as dust settles from FCA investigation

“The two major risks facing PFG were the outcome of the FCA’s investigation into ROP and a potential funding gap. These have now been neutralised and the group can focus on recovery,” said the broker

Provident Financial building
The sub-prime lender had to pay £172mln to settle the ROP investigation at Vanquis Bank

City broker Liberum has upgraded its rating for Provident Financial (LON:PFG) to ‘Buy’ following the conclusion of a regulatory investigation into its credit card Repayment Option Plan (ROP) and a rights issue.

“The two major risks facing PFG were the outcome of the FCA’s investigation into ROP and a potential funding gap.

“These have now been neutralised and the group can focus on recovery,” said the broker.

READ: Provident Financial rallies strongly as City focuses on recovery potential

The FTSE 250-listed sub-prime lender had to pay £172mln to settle the ROP investigation at Vanquis Bank, Provident’s credit card arm.

Major shareholders Invesco (NYSE:IVZ) and Woodford Investment Management (LON:WPCT) also backed the £331mln rights issue, which Liberum said had resolved the issue of the potential funding gap.

“Upside risks include revenues from new ROP sales coming back online. Downside risks include higher impairment rates in Vanquis, particularly from the existing book”.

Provident shares were little changed at 978.4p.

Quick facts: Provident Financial

Price: 182.8 GBX

LSE:PFG
Market: LSE
Market Cap: £463.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

6 hours, 21 minutes ago

2 min read